Advertisement

Advertisement
Breast Cancer

T-DXd Approved by the FDA for Pretreated Patients With HER2-Low or -Ultralow Metastatic Breast Cancer

The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has been approved by the U.S. Food and Drug Administration...


Lung Cancer

Anatomic Lung Resection May Be Linked to Improved Survival in Early-Stage NSCLC

Anatomic lung resections such as lobectomy and segmentectomy may be associated with improved long-term survival...

Colorectal Cancer

Novel Combination Targeted Therapies, Chemotherapy in BRAF-Mutated Metastatic Colorectal Cancer

First-line treatment with the targeted therapies encorafenib and cetuximab plus a modified leucovorin, fluorouracil, and oxaliplatin...


Advertisement
Colorectal Cancer

New Findings on Aspirin and Risk of Colorectal Cancer Recurrence

According to one of the first biomarker-driven randomized study in people with nonmetastatic colorectal cancer, taking 160 mg of aspirin daily...

Colorectal Cancer

New Research Explores Blood Test to Determine Prognosis, Benefit of Celecoxib in Stage III Colon Cancer

Previous research has shown that nonsteroidal antiinflammatory drugs (NSAIDs), including aspirin and COX-2 inhibitors...

Advertisement
Advertisement




More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Colorectal Cancer

Experimental Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer

The BRAF inhibitor encorafenib plus the monoclonal antibody cetuximab combined with mFOLFOX (modified folinic acid, fluorouracil, and oxaliplatin) significantly improved overall response in BRAF V600E–mutant metastatic colorectal cancer, according to data presented at the 2025 ASCO Gastrointestinal ...

Advertisement

Flagellin and Immune Checkpoint Inhibition in Patients With Ovarian Cancer

The interference of gut bacteria could explain the ineffectiveness of immune checkpoint therapy in some patients with ovarian cancer, according to a recent study published by McGinty et al in Cancer Immunology Research.  Background There are over 10,000 ovarian cancer–related deaths in the United...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Leukemia
Myelodysplastic Syndromes

FDA Approves Preparative Regimen for Allogeneic HSCT in Patients With AML or MDS

On January 21, the U.S. Food and Drug Administration (FDA) approved treosulfan (Grafapex), an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia ...

Colorectal Cancer

Dual Immunotherapy Extended Progression-Free Survival in Metastatic Colorectal Cancer Subgroup

An immunotherapy combination for advanced, highly mutated colorectal cancer has significantly delayed disease progression vs single-agent therapy, according to data presented at the 2025 ASCO Gastrointestinal Cancers Symposium.1 The phase III CheckMate 8HW trial compared the PD-1 inhibitor...

Colorectal Cancer Treatment Resistance: Oncofetal Reprogramming

Researchers may have uncovered a major factor contributing to treatment resistance in patients with colorectal cancer, according to a recent study published by Mzoughi et al in Nature Genetics. Background Colorectal cancer is one of the deadliest cancer types across the world, with treatment...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Leukemia

Novel Menin Inhibitors Show Safety and Activity in Several Clinical Trials

The recently approved menin inhibitor revumenib is poised to improve the treatment of acute myeloid leukemia (AML), specifically for disease with a KMT2A rearrangement. Promising results for other novel menin inhibitors now in development—with their unique safety and activity profiles—suggest the...

Advertisement

ctDNA and Immunoscore in Resected Stage III Colon Cancer

As reported in the Journal of Clinical Oncology by Taieb et al, a combined analysis of two phase III adjuvant trials (IDEA-France and IDEA-Greece) in stage III colon cancer showed that the presence of circulating tumor DNA (ctDNA) after surgery was prognostic for poorer outcomes and that...

ASCO Post X Feed
Social Media Hub by Everwall